Evidence map›Paper›PMID 39869159›Full record

ArticleCellular and molecular life sciences : CMLS2025

M

Yongming Cheng, Rong Han, Meiqi Wang, Shuqing Wang, Junliang Zhou, Jianyi Wang, Hui Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yongming Cheng *Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China.
Rong Han *Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China.
Meiqi Wang *Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China.
Shuqing WangDepartment of Clinical Laboratory, Harbin Fourth Hospital, 119 Jingyu Road, Harbin, 150001, China.
Junliang ZhouDepartment of Clinical Laboratory, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China.
Jianyi WangDepartment of Clinical Laboratory, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China.
Hui XuDepartment of Clinical Laboratory, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China. xuhui@hrbmu.edu.cn.ORCID http://orcid.org/0000-0002-7596-8011

Funding

Basic Research Program for Provincial Universities of Heilongjiang Province 2023-KYYWF-0220Natural Science Foundation of Heilongjiang Province LH2023H092
6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) has emerged as one of the most prevalent malignancies worldwide. N6-methyladenosine (m

Indexed as

AdenosineCarcinoma, Non-Small-Cell LungLung NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Long NoncodingCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMethyltransferasesSignal TransductionAdenosineMethyltransferasesMETTL3 protein, humanN-methyladenosinePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Long NoncodingDNA damageEpigenetic modificationsEpithelial–mesenchymal transitionHomologous recombination repairN6-methyladenosine methylation

Identifiers

PMID39869159
PMCPMC11772919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.